David Phillips has more than 27 years of extensive expertise in establishing the foundations of quality departments in multiple pharmaceutical and biotech companies. Prior to joining Vor Bio, David served as Vice President, Head of Quality at Beam Therapeutics where he built the quality management system from the ground up, spanning all GxP areas. He also served as Vice President, Head of Quality at Kiniksa Pharmaceuticals where he established the company’s overall strategic long-term vision for quality. Before Kiniksa, David was Vice President, Quality at Shire Pharmaceuticals prior to its acquisition by Takeda. Notably, David was a core member of the team responsible for the integration of a number of programs and companies acquired by Shire and was responsible for various aspects of quality product lifecycle planning, quality aspects of geographic expansion, and technical oversight of key quality functions across a network of more than 25 locations.
David’s experience working outside of the United States – at Lonza Biologics in Singapore and at VaxGen, Inc./Celltrion in South Korea– provides him with a valuable global perspective. While at Lonza, he helped establish the country’s first biologics manufacturing park. David holds an MBA in new product development and project management and a Bachelor of Science in biochemistry and polymer chemistry from the North Carolina State University.